HepQuant Receives FDA Approval for SHUNT Liver Diagnostic Test

HepQuant, a member of Fitzsimons Innovation Community, has received premarket approval from the U.S. Food and Drug Administration (FDA) for its SHUNT Liver Diagnostic Test, marking a significant regulatory milestone for the company’s liver disease diagnostic technology.

The blood-based test measures liver function and helps clinicians identify certain patients with compensated cirrhosis who are unlikely to have large esophageal varices, potentially informing decisions about invasive screening procedures. The approval follows years of scientific development and clinical validation, advancing HepQuant’s efforts to improve liver disease assessment and patient management.

Read the full announcement: FDA Approves the HepQuant SHUNT Liver Diagnostic Test

Source: HepQuant